Pulmonary Hypertension and the Gut Microbiome
The gut microbiome and its associated metabolites are integral to the maintenance of gut integrity and function. There is increasing evidence that its alteration, referred to as dysbiosis, is involved in the development of a systemic conditions such as cardiovascular disease (e.g., systemic hypertension, atherosclerosis). Pulmonary hypertension (PH) is a condition characterised by progressive remodelling and vasoconstriction of the pulmonary circulation, ultimately leading to right ventricular failure and premature mortality if untreated. Initial studies have suggested a possible association between dysbiosis of the microbiome and the development of PH. The aim of this article is to review the current experimental and clinical data with respect to the potential interaction between the gut microbiome and the pathophysiology of pulmonary hypertension. It will also highlight possible new therapeutic targets that may provide future therapies.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
---|---|
Enthalten in: |
Biomedicines - 12(2024), 1 vom: 12. Jan. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Mason, Thomas [VerfasserIn] |
---|
Links: |
---|
Themen: |
Dysbiosis |
---|
Anmerkungen: |
Date Revised 28.01.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3390/biomedicines12010169 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM367457571 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM367457571 | ||
003 | DE-627 | ||
005 | 20240128232021.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240123s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/biomedicines12010169 |2 doi | |
028 | 5 | 2 | |a pubmed24n1273.xml |
035 | |a (DE-627)NLM367457571 | ||
035 | |a (NLM)38255274 | ||
035 | |a (PII)169 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Mason, Thomas |e verfasserin |4 aut | |
245 | 1 | 0 | |a Pulmonary Hypertension and the Gut Microbiome |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 28.01.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a The gut microbiome and its associated metabolites are integral to the maintenance of gut integrity and function. There is increasing evidence that its alteration, referred to as dysbiosis, is involved in the development of a systemic conditions such as cardiovascular disease (e.g., systemic hypertension, atherosclerosis). Pulmonary hypertension (PH) is a condition characterised by progressive remodelling and vasoconstriction of the pulmonary circulation, ultimately leading to right ventricular failure and premature mortality if untreated. Initial studies have suggested a possible association between dysbiosis of the microbiome and the development of PH. The aim of this article is to review the current experimental and clinical data with respect to the potential interaction between the gut microbiome and the pathophysiology of pulmonary hypertension. It will also highlight possible new therapeutic targets that may provide future therapies | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a dysbiosis | |
650 | 4 | |a gut microbiome | |
650 | 4 | |a pulmonary hypertension | |
700 | 1 | |a Mukherjee, Bhashkar |e verfasserin |4 aut | |
700 | 1 | |a Marino, Philip |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Biomedicines |d 2013 |g 12(2024), 1 vom: 12. Jan. |w (DE-627)NLM268899797 |x 2227-9059 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2024 |g number:1 |g day:12 |g month:01 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/biomedicines12010169 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 12 |j 2024 |e 1 |b 12 |c 01 |